5-羟色胺对重症社区获得性肺炎严重程度的预测研究

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (9): 1195-1200.

5-羟色胺对重症社区获得性肺炎严重程度的预测研究

何权¹, 刘丹瑜^2,3, 叶君¹, 张艳丽¹, 朱华栋², 蒋澄宇^1*, 徐军^2*

1.中国医学科学院基础医学研究所北京协和医学院基础学院生物化学与分子生物学系,北京 100005;
2.中国医学科学院北京协和医学院北京协和医院急诊科,北京 100730;
3.北京大学第一医院呼吸和危重症医学科,北京 100034

收稿日期:2020-07-12 修回日期:2020-07-24 出版日期:2020-09-05 发布日期:2020-09-04
通讯作者: ^*jiang@pumc.edu.cn; xujunfree@126.com
基金资助:
国家自然科学基金委员会科学中心项目(81788101);中国医学科学院医学与健康科技创新工程(2017-I2M-1-009)

Predictive research of 5-hydroxytryptamine in severity of severe community-acquired pneumonia

HE Quan¹, LIU Dan-yu^2,3, YE Jun¹, ZHANG Yan-li¹, ZHU Hua-dong², JIANG Cheng-yu^1*, XU Jun^2*

1. Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC, Beijing 100005;
2. Department of Emergency, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730;
3. Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China

Received:2020-07-12 Revised:2020-07-24 Online:2020-09-05 Published:2020-09-04
Contact: ^*jiang@pumc.edu.cn; xujunfree@126.com

摘要/Abstract

摘要： 目的利用非靶向代谢组学分析方法,探寻重症社区获得性肺炎(SCAP)潜在预后标志物。方法采用液相色谱质谱联用分析技术(LC-MS),对2015年1月至2019年6月收集于北京协和医院的30名健康成人志愿者和68例重症社区获得性肺炎患者的血浆样本进行代谢物检测。根据临床预后,患者可分为存活组(n=49)和死亡组(n=19)。采用多元统计分析方法OPLS-DA和单变量统计分析方法Kruskal Wallis检验筛选差异代谢物。对差异代谢物进行预后分析和相关性分析。结果液相色谱质谱联用分析技术检测出健康成人与重症社区获得性肺炎患者共有代谢物3 463个。OPLS-DA和Kruskal Wallis Test分析方法筛选出差异代谢物126个。5-羟色胺(5-HT)在存活组和死亡组间具有显著性差异(P＜0.05,AUC＞0.75)。5-HT与氧合指数(OI)呈正相关,与急性生理与慢性健康评分Ⅱ(APACHEⅡ)呈负相关。结论 5-HT能够预测重症社区获得性肺炎患者的预后,可作为预后预测的潜在生物标志物。

关键词: 5-羟色胺(5-HT), 重症社区获得性肺炎(SCAP), 预后标志物, 代谢组学

Abstract: Objective To search for potential prognostic markers for severe community-acquired pneumonia (SCAP) using non-targeted metabolomics. Methods Testing plasma samples from 30 healthy people and 68 SCAP patients (all collected from January 2015 to June 2019 at Peking Union Medical College Hospital) by liquid chromatography mass spectrometry (LC-MS). According to clinical prognosis, patients were divided into survive group (n=49) and non-survive group (n=19). OPLS-DA (multivariate statistical analysis) and Kruskal Wallis Test (single variable statistical analysis) were used to identify differential metabolites. Correlation analysis of clinical indicators and prognostic analysis were also used for differential metabolites. Results Totally 3 463 metabolites were detected in healthy people and SCAP patients by LC-MS. Among them, 126 metabolites were screened out by OPLS-DA andKruskal Wallis Test analysis methods. Prognostic analysis showed that the quantity of 5-hydroxytryptamine(5-HT) was significantly different between survive group and non-survive group (P＜0.05, AUC＞0.75). Correlation analysis of clinical indicators showed that 5-HT was positively correlated with oxygenation index (OI) and negatively correlated with acute physiology and chronic health evaluation Ⅱ (APACHE Ⅱ) score. Conclusions The 5-HT as a potential prognostic marker for SCAP, may predict the prognosis of SCAP patients.

Key words: 5-hydroxytryptamine(5-HT), severe community-acquired pneumonia(SCAP), prognostic markers, metabolomics

中图分类号:

R181.3+8

何权, 刘丹瑜, 叶君, 张艳丽, 朱华栋, 蒋澄宇, 徐军. 5-羟色胺对重症社区获得性肺炎严重程度的预测研究[J]. 基础医学与临床, 2020, 40(9): 1195-1200.

HE Quan, LIU Dan-yu, YE Jun, ZHANG Yan-li, ZHU Hua-dong, JIANG Cheng-yu, XU Jun. Predictive research of 5-hydroxytryptamine in severity of severe community-acquired pneumonia[J]. Basic & Clinical Medicine, 2020, 40(9): 1195-1200.

参考文献

[1] Leoni D, Rello J. Severe community-acquired pneumonia: optimal management[J]. Curr Opin Infect Dis, 2017, 30:240-247.
[2] Lanks CW, Musani AI, Hsia DW. Community-acquired pneumonia and hospital-acquired pneumonia[J]. Med Clin North Am, 2019, 103:487-501.
[3] Singanayagam A, Chalmers JD, Hill AT. Severity assessment in community-acquired pneumonia: a review[J]. QJM, 2009, 102: 379-388.
[4] Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality[J]. Thorax, 2009, 64: 1062-1069.
[5] Kolditz M, Ewig S, Höffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers[J]. Eur Respir J, 2013, 41:974-984.
[6] Zhang A, Sun H, Wang X. Saliva metabolomics opens door to biomarker discovery, disease diagnosis, and treatment[J]. Appl Biochem Biotechnol, 2012, 168:1718-1727.
[7] Nicholson JK, Lindon JC. Systems biology: Metabonomics[J]. Nature, 2008, 455:1054-1056.
[8] Gershon MD. Serotonin: its role and receptors in enteric neurotransmission[J]. Adv Exp Med Biol, 1991, 294:221-230.
[9] Andrews PW, Bharwani A, Lee KR, et al. Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response[J]. Neurosci Biobehav Rev, 2015, 51:164-188.
[10] Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for func-tional GI disorders[J]. Gastroenterology, 2007, 132:397-414.
[11] Margolis KG, Gershon MD. Enteric neuronal regulation of intestinal Inflammation[J]. Trends Neurosci, 2016, 39: 614-624.
[12] Miller MJ. Tissue oxygenation in clinical medicine: an historical review[J]. Anesth Analg, 1982, 61:527-535.
[13] Krafft P, Steltzer H, Hiesmayr M, et al. Mixed venous oxygen saturation in critically ill septic shock patients. The role of defined events[J]. Chest, 1993, 103:900-906.
[14] Liu W, Peng L, Hua S. Clinical significance of dynamic monitoring of blood lactic acid, oxygenation index and C-reactive protein levels in patients with severe pneumonia[J]. Exp Ther Med, 2015, 10:1824-1828.